<DOC>
	<DOCNO>NCT00001416</DOCNO>
	<brief_summary>The purpose study examine skeleton responds repeat dos enzyme replacement therapy patient type I Gaucher 's disease spleens remove . Gaucher disease lysosomal storage disease result glycocerebroside accumulation macrophage due genetic deficiency enzyme glucocerebrosidase . It may occur adult occur severely infant , cerebroside also accumulate neuron . Patients Gaucher 's disease experience enlargement liver spleen bone destruction . The condition pass generation generation autosomal recessive inheritance . Type I common form . It chronic non-neuronopathic form , mean disease affect nerve cell . The symptoms type I appear age . In study patient divide three group . Each group receive different dos enzyme replacement ( Ceredase ) . In addition , two three group also receive dos form vitamin D ( calcitriol ) . Researchers believe group receive vitamin D improve response compare patient receive enzyme replacement . Patients group respond enzyme replacement increase bone density compare treatment group .</brief_summary>
	<brief_title>Bone Response Enzyme Replacement Gaucher 's Disease</brief_title>
	<detailed_description>The purpose study examine response skeleton repeat infusion macrophage-targeted glucocerebrosidase ( CEREDASE ( Trademark ) ) splenectomized patient type I Gaucher 's disease . The magnitude rate development skeletal response monitor non-invasively . Theoretically , enhance response occur patient supplement pharmacologic dos 1 , 25-dihydroxyvitamin D3 ( calcitriol ) , since calcium absorption enzyme delivery bone marrow macrophage increase set . These issue address clinical trial us modify factorial design . A total 57 patient assign three treatment group block randomization . Group 1 : CEREDASE ( Trademark ) ( 60 IU/kg q2wks ; 0-6 month ) CEREDASE ( Trademark ) ( 30 IU/kg q2wks ; 7-24 month ) Group 2 : Calcitriol ( 0.25-3.0 micrograms/day ; 0-24 month ) CEREDASE ( Trademark ) ( 60 IU/kg q2wks ; 7-12 month ) CEREDASE ( Trademark ) ( 30 IU/kg q2wks ; 13-24 month ) Group 3 : Calcitriol ( 0.25-3.0 micrograms/day ; 0-24 month ) CEREDASE ( Trademark ) ( 60 IU/kg q2wks ; 0-6 month ) CEREDASE ( Trademark ) ( 30 IU/kg q2wks ; 7-24 month ) The number patient respond enzyme replacement significant decrease hepatic volume significant increase trabecular bone density lumbar spine compare treatment group .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Splenectomized Gaucher patient . Aged 1845 receive enzyme therapy least 1 year . No patient illness ( pulmonary , liver , kidney , bone , hematologic ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bone Disease</keyword>
	<keyword>Calcitriol</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Gaucher 's Disease</keyword>
	<keyword>Vitamin D</keyword>
</DOC>